Stocks
Concert Pharmaceuticals IncCNCE
HealthcareBiotechnology
A clinical-stage biopharmaceutical company developing small molecule therapeutics for the treatment of serious diseases, with a primary focus on alopecia areata. Its lead candidate, CTP-543, has shown promising results in Phase 3 trials, making it a key stock to watch for investors interested in dermatology and immunology. The company was acquired by Sun Pharma in 2023.
Congressional Interest in Concert Pharmaceuticals Inc (CNCE)
1 member of Congress has disclosed 1 trade in Concert Pharmaceuticals Inc (CNCE), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading CNCE?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-01-18 | MICHAEL T. MCCAUL | sell | $1K-$15K |